Novel drug delivery system aims to prevent hearing loss from cisplatin chemotherapy

The chemotherapy drug cisplatin is a lifesaver for many adults and children diagnosed with cancer, but it often causes hearing loss, a side effect that can diminish quality of life following treatment.

Brenzavvy vs Farxiga for T2D; PFAS in Seafood; 100 Deaths Linked to GLP-1 Drugs?

Bexagliflozin (Brenzavvy) and dapagliflozin (Farxiga) induced similar HbA1c reductions over 24 weeks in a head-to-head phase III trial of the SGLT2 inhibitors in Chinese adults

April 17, 2024

Microbial signatures linked to immunotherapy response across cancers

The microbiome can identify those who benefit from combination immunotherapy across multiple different cancers, including rare gynecological cancers, biliary tract cancers and melanoma.

March 2, 2024

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Conference 11.01.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

January 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.